Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders.
Autor(es): Chiang Han-Lin,Lyu Rong-Kuo,Tseng Mu-Yun,Chang Kuo-Hsuan,Chang Hong-Shiu,Hsu Wen-Chuin,Kuo Hung-Chou,Chu Chun-Che,Wu Yih-Ru,Ro Long-Sun,Huang Chin-Chang,Chen Chiung-Mei
Resumo: Guillain-Barré syndrome (GBS) is an autoimmune inflammatory polyradiculoneuropathy that causes acute areflexic paralysis with a high risk of respiratory failure. Previously, using two-dimensional gel electrophoresis and mass spectrometry, we found that the transthyretin level was altered in the cerebrospinal fluid (CSF) of GBS patients when compared to that in CSF of control patients. We used enzyme-linked immunosorbent assay (ELISA) to measure the transthyretin levels in the CSF and serum from 22 GBS, 4 Miller-Fisher syndrome (MFS), 9 chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 22 multiple sclerosis (MS), 10 Alzheimer's disease (AD), and 6 viral meningitis (VM) patients, and 18 controls. The results show that CSF transthyretin concentration of the GBS patients is significantly higher than that of the control, MS, AD and VM patients (p<0.05), although not significantly different from that of MFS and CIDP patients. The increased CSF transthyretin level may be explained by barrier dysfunction or decreased CSF flow in the GBS patients along with increased intrathecal synthesis of transthyretin that might be a protective response to nerve damage.
Imprenta: Clinica Chimica Acta; International Journal of Clinical Chemistry, v. 405, n. 1-2, p. 143-147, 2009
Identificador do objeto digital: 10.1016/j.cca.2009.04.022
Descritores: Guillain-Barre Syndrome - Proteins
Data de publicação: 2009
